Significant Investments in International Biopharma Hub in South Korea
Sartorius is investing substantially in expanding its activities in South Korea. The site in South Korea’s major Biopharma hub Songdo in Incheon is going to feature consumables and cell culture media production, as well as an application and training center with laboratories, services, logistics, and other operations.
In October 2022, Sartorius Korea signed a land purchase agreement with the IFEZ (Incheon Free Economic Zone Authority). Groundwork started at the beginning of 2023. Operations are planned to start in 2026.
Job Opportunities
Sartorius is offering positions in South Korea and throughout Asia.
Facts & Figures
Area
25,000 m2
in major Biopharma hub
Start of Construction
2023
Preparation and groundwork
Start of Operations
2026
plus laboratory and training center
Impressions from the Songdo Site
Supporting Customer Growth
Products for Efficient and Flexible Production of Biopharmaceuticals
The facility will cover some 93,000 square meters. Once the site will be operational, the manufacturing portfolio will include numerous products and solutions for fluid management, cell culture media, membrane filtration, and others.
Sartorius Songdo
211-1, Songdo-dong, Yeonsu-gu, Incheon, South Korea
Phone: +82 31 622 5700
Mail: info@sartorius.co.kr
